INCB052793
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for INCB052793, covering 2020-04-17 to 2020-04-17. Get the full timeline:
Most recent: Clinical Trial Update: An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies [Phase 1, Phase 2]